1. Clinical Overview
A fixed-dose combination inhaler containing Levosalbutamol (the active R-enantiomer of Salbutamol) and Ipratropium Bromide. Levosalbutamol is a selective short-acting beta2-adrenergic agonist (SABA) providing rapid bronchodilation, while Ipratropium is a short-acting muscarinic antagonist (SAMA) that provides complementary bronchodilation via a different pathway. This combination is synergistic, offering superior bronchodilation compared to monotherapy, particularly in patients with moderate to severe airflow obstruction. It is a cornerstone in the management of acute exacerbations of obstructive airway diseases in the Indian clinical setting.
| Onset | Duration | Bioavailability |
|---|---|---|
| Levosalbutamol: 5-15 minutes. Ipratropium: 15-30 minutes. | Levosalbutamol: 3-6 hours. Ipratropium: 4-6 hours. | Levosalbutamol: ~10% of inhaled dose reaches lungs; systemic bioavailability is low. Ipratropium: Minimal systemic absorption (~10-30% of inhaled dose); majority is swallowed and poorly absorbed from GI tract. |
2. Mechanism of Action
The combination works synergistically via two distinct pathways to achieve bronchodilation. Levosalbutamol stimulates intracellular adenylate cyclase via beta2-adrenergic receptors, increasing cyclic AMP (cAMP), leading to relaxation of bronchial smooth muscle. Ipratropium competitively inhibits acetylcholine at muscarinic (M3) receptors on bronchial smooth muscle and submucosal glands, blocking vagally mediated bronchoconstriction and mucus secretion. This dual blockade of sympathetic and parasympathetic pathways provides more complete and potent bronchodilation than either agent alone.
3. Indications & Uses
- Acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
- Moderate to severe acute bronchospasm in Asthma (as per physician discretion, though not first-line for acute asthma per GINA)
4. Dosage & Administration
Adult Dosage: The standard dose is 2 puffs (each puff containing Levosalbutamol 0.63mg + Ipratropium 500mcg) via MDI, inhaled 4 times a day as needed for symptom relief or during exacerbations. Maximum: 12 puffs in 24 hours. For Respimat inhaler: 1 puff (equivalent dose) 4 times daily.
Administration: 1. Shake the MDI canister well before use. 2. Exhale fully. 3. Place mouthpiece between lips, forming a tight seal. 4. Activate the inhaler at the start of a slow, deep inhalation. 5. Hold breath for 5-10 seconds. 6. Wait at least 30-60 seconds before the second puff. 7. Rinse mouth with water after use to prevent oral thrush and systemic absorption. Use a spacer device if coordination is poor.
5. Side Effects
Common side effects may include:
- Dry mouth (xerostomia)
- Throat irritation or hoarseness
- Cough immediately after inhalation
- Headache
- Taste disturbance
- Palpitations (mild)
- Nervousness or tremor
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Beta-Adrenergic Agonists (Oral/Inhaled) | Additive sympathomimetic effects, increased risk of tachycardia, hypokalemia, arrhythmias. | Major |
| Beta-Adrenergic Blockers (e.g., Propranolol) | Antagonizes bronchodilator effect of Levosalbutamol; may induce severe bronchospasm in asthmatics. | Major |
| Diuretics (Loop/Thiazide) | Concomitant use with high-dose beta-agonists may potentiate hypokalemia. | Moderate |
| Monoamine Oxidase Inhibitors (MAOIs) & Tricyclic Antidepressants (TCAs) | May potentiate the cardiovascular effects (hypertension, tachycardia) of Levosalbutamol. | Moderate |
| Xanthine derivatives (Theophylline) | Additive cardiovascular stimulant effects; increased risk of arrhythmias. | Moderate |
| Anticholinergic drugs (e.g., Tiotropium, Aclidinium, Atropine, Antihistamines, Phenothiazines) | Additive anticholinergic side effects (dry mouth, urinary retention, constipation, blurred vision). | Moderate |
| Digoxin | Hypokalemia from beta-agonists may increase risk of digoxin toxicity. | Moderate |
| Corticosteroids (Systemic) | May enhance hypokalemic effect of beta-agonists. | Moderate |
7. Patient Counselling
- DO use exactly as prescribed by your doctor.
- DO shake the inhaler well before each use.
- DO rinse your mouth with water and spit it out after each use to prevent thrush.
- DO use a spacer device if recommended by your doctor for better drug delivery.
- DO keep track of the number of puffs used to know when the canister is empty.
- DONT exceed the maximum recommended daily puffs.
- DONT stop your maintenance controller medications (like inhaled corticosteroids) when using this reliever.
- DONT spray the medication into your eyes. If it happens, rinse eyes with water immediately.
- DONT use this inhaler for conditions other than breathing difficulty as directed.
8. Toxicology & Storage
Overdose: Symptoms are extensions of pharmacologic effects: Levosalbutamol overdose: Tachycardia, arrhythmias (including atrial fibrillation, supraventricular tachycardia), tremor, headache, hypokalemia, hyperglycemia, metabolic acidosis, angina. Ipratropium overdose: Intensified anticholinergic effects: severe dry mouth, blurred vision, urinary retention, constipation, tachycardia, nervousness, dizziness, confusion.
Storage: Store at room temperature (15-30°C). Protect from direct sunlight, heat, and frost. Do not puncture or incinerate the canister, even when empty. Keep out of reach of children. Do not store near open flame or heat source. The canister is under pressure.